Many of us find the prospect of investing in international stocks scary. With all the news lately about Europe's financial crisis and a big slowdown in emerging-market economies like China, that fear may seem justified.
But when an entire country's stock market gets crushed due to wider economic concerns, some promising stocks get unfairly punished.
Here are five foreign companies whose shares are trading now at attractive prices, along with explanations for why they're such bargains, and what their future prospects are.
5 Foreign Stocks Trading at Bargain-Basement Prices
5 Foreign Stocks You Can Snap Up at Bargain-Basement Prices
What it does: Eni (E) is an Italian energy company that combines all three major businesses of the oil and gas industry -- exploration and production, transport and storage, and refining and marketing -- under one corporate umbrella.
Why it's a bargain: Italy has been near the epicenter of the European financial crisis, and the results of its recent election sent its stock market plunging as many investors fear the new government could undo hard-won austerity measures and send the Eurozone back into economic chaos. Eni fell along with its home market, but it has a global energy business that's more dependent on worldwide conditions than on those in any one area. With the stock trading at just eight times earnings, Eni's price makes its shares attractive even given the headwinds Europe faces.
What it does: Tata (TTM) is an Indian automaker producing cars and trucks for both commercial and personal use. Although it's gotten its fair share of publicity globally for its $2,000 Nano compact car, it is less widely known as the company that now makes luxury brands Jaguar and Land Rover.
Why it's a bargain: India is still growing at a much faster rate than the U.S., but forecasts see that growth rate slowing this year. And while it dominates the low-priced car market in India, Tata has seen margins at Jaguar Land Rover fall sharply. Nevertheless, the share price already reflects much of this expected slowdown, and with the stock fetching just seven times what it has earned in the past 12 months, Tata has great long-term potential once India gets back into faster-growth mode.
What it does: Telefonica (TEF) is a Spanish company providing telephone, Internet, and video services to customers in Europe and Latin America.
Why it's a bargain: Like Italy, Spain has had major economic troubles that have contributed to Europe's overall problems. To conserve cash, Telefonica decided to suspend its lucrative dividend, which scared some income investors out of the stock. But with its Latin American business still doing well and the stock trading at just seven times earnings, Telefonica has both promising growth prospects and a bargain share price to compensate shareholders of taking on some European economic risk.
What it does: Seagate (STX) is a major manufacturer of hard drives for computers. It moved its headquarters to Ireland in 2010, but it still has extensive operations in the U.S. and elsewhere around the world.
Why it's a bargain: The rise of tablets and smartphones has hurt the PC industry, which is a big buyer of hard drives. Moreover, as newer technologies like solid-state drives and flash memory become even more cost-effective, investors fear that Seagate's traditional disk drives will become obsolete. Yet Seagate has taken steps to stay relevant with its own solid state drives, and with a price-to-earnings ratio of just 4, even anticipated declines in net income don't make the stock look expensive.
What it does: AstraZeneca (AZN) is a U.K.-based pharmaceutical company. Its best-selling drugs have included cholesterol drug Crestor and its Nexium acid-reflux drug.
Why it's a bargain: AstraZeneca has been hit hard by the loss of patent protection on some of its blockbuster drugs, especially the antipsychotic Seroquel, sales of which dropped by $3 billion last year due to generic competition. But there are other drugs in its pipeline that could eventually replace the profits generated by those past blockbusters, including diabetes treatment Bydureon. At this point, AstraZeneca's P/E of 9 reflects patent-loss pessimism and leaves room for upside if the company's stable of drugs in development pans out well.